Published in final edited form as:

AIDS Care. 2017 July ; 29(7): 846–850. doi:10.1080/09540121.2016.1271393.

Identifying HIV Care Enrollees At-Risk for Cannabis Use Disorder

Bryan Hartzler¹, Beatriz H. Carlini¹, Howard Newville¹, Heidi M. Crane², Joseph J. Eron^{3,4}, Elvin H. Geng⁵, W. Christopher Mathews⁶, Kenneth H. Mayer^{7,8,9}, Richard D. Moore^{10,11,12}, Michael J. Mugavero¹³, Sonia Napravnik³, Benigno Rodriguez¹⁴, and Dennis M. Donovan^{1,15}

¹Alcohol & Drug Abuse Institute, University of Washington, Seattle WA ²Division of Allergy and Infectious Disease, University of Washington, Seattle WA ³Department of Medicine, University of North Carolina, Chapel Hill NC ⁴Department of Epidemiology, University of North Carolina, Chapel Hill NC ⁵School of Medicine, University of California, San Francisco CA ⁶Department of Medicine, University of California, San Diego CA ⁷School of Medicine, Harvard University, Boston MA ⁸School of Public Health, Harvard University, Boston MA ⁹Fenway Health, Boston MA ¹⁰Department of Medicine, Johns Hopkins University, Baltimore MD ¹¹Department of Epidemiology, Johns Hopkins University, Baltimore MD ¹²Center for Global Health, Johns Hopkins University, Baltimore MD ¹³Department of Medicine, University of Alabama, Birmingham AL ¹⁴Department of Medicine, Case Western Reserve University, Cleveland ¹⁵Psychiatry and Behavioral Sciences, University of Washington, Seattle WA

Abstract

Increased scientific attention given to cannabis in the United States has particular relevance for its domestic HIV care population, given that evidence exists for both cannabis as a therapeutic agent and cannabis use disorder (CUD) as a barrier to antiretroviral medication adherence. It is critical to identify relative risk for CUD among demographic subgroups of HIV patients, as this will inform detection and intervention efforts. A Center For AIDS Research Network of Integrated Clinical Systems cohort (N=10,652) of HIV-positive adults linked to care at seven U.S. sites was examined for this purpose. Based on a patient-report instrument with validated diagnostic threshold for CUD, the prevalence of recent cannabis use and corresponding conditional probabilities for CUD were calculated for the aggregate sample and demographic subgroups. Generalized estimating equations then tested models directly examining patient demographic indices as predictors of CUD, while controlling for history and geography. Conditional probability of CUD among cannabis-using patients was 49%, with the highest conditional probabilities among demographic subgroups of young adults and those with non-specified sexual orientation (67–69%) and the lowest conditional probability among females and those 50+ years of age (42% apiece). Similarly, youthful age and male gender emerged as robust multivariate model predictors of CUD. In the context of increasingly lenient policies for use of cannabis as a therapeutic agent for chronic conditions like HIV/AIDS, current study findings offer needed direction in terms of specifying

targeted patient groups in HIV care on whom resources for enhanced surveillance and intervention efforts will be most impactful.

Keywords

Cannabis Use Disorder; HIV/AIDS; Care Settings; United States

Increased scientific attention to cannabis encompasses its potential as a therapeutic agent for some health conditions and impetus to public health challenges. Both sides of this pendulum impact persons living with HIV/AIDS (PLWHA). Cannabis has benefits for managing weight loss, neuropathy, nausea, and pain (Abrams et al., 2007; Cohen, Heinz, Ilgen, & Bonn-Miller, 2016; de Jong, Prentiss, McFarland, Machekano, & Israelski, 2005; Lutge, Gray, & Siegfried, 2013), yet cannabis use disorder (CUD) is linked to poor antiretroviral medication adherence and virologic outcomes (Bonn-Miller, Oser, Bucossi, & Trafton, 2014). In the U.S., a 23% cannabis use rate among PLWHA more than triples that of the general population (SAMHSA, 2011), though estimates do vary by demography (Hosek, Harper, & Domanico, 2005; Marshall et al., 2015). That some PLWHA use cannabis to effectively manage aspects of their health (Fogarty et al., 2007; Furler, Einderson, Millson, Walmsley, & Bendayan, 2004) and others develop a dependence syndrome broadly characteristic of that seen for alcohol, tobacco, and illicit drugs (Budney & Hughes, 2006) underscores a need to identify HIV care enrollees at-risk for CUD.

Lack of diagnostic specificity and caveats common to single-site trials (i.e., selection bias, geographic isolation, historical artifact) have limited the evidence regarding the domestic prevalence of CUD in extant HIV care literature. However, recent work (Hartzler et al., in press), based on a 10,000+ Center For AIDS Research Network of Integrated Clinical Systems (CNICS) cohort, more conclusively estimates CUD prevalence at 31%. The current study seeks to document lifetime prevalence rates of cannabis use, conditional probabilities of CUD among cannabis users, and demographic predictors of CUD in this CNICS cohort. Given ongoing movement toward more lenient cannabis policies for specified medical conditions including HIV/AIDS, findings may identify HIV care enrollees for whom targeted surveillance and intervention efforts will be most impactful.

Methods

This report utilized CNICS (2016), an open access platform initiated in 1995 for longitudinal observation of PLWHA linked to care. Available data derive from documentation of patient care visits, medication/laboratory information, and patient-reports collected via web-based survey. Continual integration of data from seven CNICS-affiliate sites enabled analyses of cannabis use rates as well as conditional probabilities and demographic predictors of CUD without sampling biases and surrogate endpoints inherent in clinical trials (Hughes, 2006).

Data Sources

This work is restricted to patient demography and 90-day retrospective reporting on the Alcohol, Smoking, and Substance Involvement Test [ASSIST; (Humeniuk et al., 2008)]. Patient demography included age, gender, ethnicity, race, transgender status, and sexual orientation (the latter collected only among recent enrollees at three sites). Cannabis reporting specified: 1) an ‘involvement score’ comprised of endorsed dependence symptoms (e.g., inability to cut down; craving; consequent role failure; health, social, legal, or financial problems) whereby a validated diagnostic threshold identified cases of CUD (Humeniuk et al., 2008), and 2) prevalence of lifetime use whereby conditional probabilities of CUD were then calculated.

Participants

The cohort (N=10,652) completed a patient-report battery at a routine clinic visit between 01/01/2007 – 12/31/2014. The CNICS-affiliate sites were at Harvard University, Johns Hopkins University, University of Alabama-Birmingham, University of California-San Diego, University of California-San Francisco, University of North Carolina-Chapel Hill, and University of Washington. Patients deemed medically unstable, appearing intoxicated, evidencing significant cognitive impairment, or unable to speak English or Spanish did not complete the assessment.

Analytic Strategy

Initial review of distributional properties for patient demography prompted decisions to: 1) create age-groups (i.e., 18–29, 30–39, 40–49, 50+ years), 2) transform race and ethnicity to a single ‘race/ethnicity’ index (non-Hispanic White, non-Hispanic Black, Hispanic, and Other), and 3) retain transgender status and sexual orientation for descriptive analyses only, given low base rate (<1%) of affirmative response for the former and poor demographic representativeness for the latter. Prevalence of lifetime cannabis use and conditional probability of CUD among reported cannabis users were computed for the aggregate sample and by demographic indices.

Given the nested multisite design, a set of generalized estimating equations (GEEs) tested population-average models for a logistic outcome (CUD, no CUD) while accounting for the nonindependence of observations among site enrollees (Hubbard et al., 2010). All models specified robust covariance structure, given the large aggregate sample size. Preliminary models revealed significant geographical variance in CUD rate among the CNICS sites, and historical variance in CUD rate among the four biennia (i.e., 2007–08, 2009–10, 2011–12, 2013–14) during which SUD assessment occurred. Thus, site and assessment biennia were included as covariates in a multivariate model. Likewise, preliminary models confirmed patient age-group, gender, and race/ethnicity as bivariate CUD predictors, prompting their inclusion in the multivariate model.

Results

Sample Demography

Age ranged from 18–84 years ($M=43.71$, $S.D.=10.62$), distributed as 12% 18–29 year-olds, 22% 30–39 year-olds, 36% 40–49 year-olds, and 30% 50+ year-olds. Gender was 83% male. Distribution of race/ethnicity was 49% Non-Hispanic White, 34% Non-Hispanic Black, 13% Hispanic, and 4% Other. Less than 1% affirmed transgender status. In the subsample ($n=1716$) self-reporting sexual orientation, 75% endorsed ‘Lesbian, Gay, or Homosexual,’ 16% ‘Straight or Heterosexual,’ 6% ‘Bisexual,’ 2% ‘Something Else,’ and 2% ‘Don’t Know.’ Table 1 notes the corresponding subsample sizes.

Prevalence of prior cannabis use and conditional probability of CUD

Table 1 also notes for the aggregate sample and each demographic index the prevalence of lifetime cannabis use and corresponding conditional probability of CUD. A majority reported cannabis use, with conditional probability of CUD approaching 50%. Prior cannabis use was particularly prevalent among those endorsing ‘Lesbian, Gay, or Homosexual’ and ‘Bisexual’ orientations (79% apiece) as well as Non-Hispanic Whites (73%). Conditional probability of CUD was most concentrated among 18–29 year-olds (67%) and two non-specified sexual orientation categories (i.e., ‘something else,’ ‘don’t know’) (67–69%).

Multivariate Prediction of CUDs

Overall model statistics revealed several effects. One was age-group, Wald $X^2(3) = 22.55$, $p<.001$, though with nonsignificant interactions with site and assessment biennia. Higher CUD rate was indicated among younger age-groups relative to 50+ year-olds. Another effect was gender, Wald $X^2(1) = 32.97$, $p<.001$, with gender X site interaction, Wald $X^2(1) = 6.42$, $p<.05$, and gender X assessment biennia interaction, Wald $X^2(1) = 4.40$, $p<.05$. The CUD rate was higher among males compared to females. Upon closer examination, the gender effect was substantive ($>10\%$ points) at three sites, modest (3–8% points) at three sites, and absent at the remaining site. Further, the gender effect was substantive (12–16% points) in 2007–2012 but more modest (8% points) in 2013–14. There was also a race/ethnicity effect, Wald $X^2(3) = 36.41$, $p<.001$, and race/ethnicity X assessment biennia interaction, Wald $X^2(3) = 13.27$, $p<.01$. Differences were modest between the ‘Other’ referent group and Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanics. Race/ethnicity variance was greatest in 2007–08 (12–20% points), but attenuated in all subsequent biennia (4–8% points). Table 2 presents beta values with 95% confidence interval limits as well as corresponding standard errors, Wald X^2 values, and odds-ratios with 95% confidence interval limits for the multivariate model.

Discussion

In this multiregional CNICS cohort, 49% of lifetime cannabis users screened positive for CUD—a rate clearly exceeding the 12–36% range reported of past-year cannabis users in community sampling efforts (Grucza, Agrawal, Krauss, Cavazos-Rehg, & Bierut, 2016; Hasin et al., 2016). Study findings include greater CUD prevalence among demographic

subgroups of young adults and those with non-specified sexual orientation, with young adulthood and male gender emerging as multivariate model predictors of CUD. Findings concerning influences of patient age and gender on CUD prevalence also mirror those of community sampling efforts, whereas absence of clear race/ethnicity influences adds to an equivocal pattern of related results (Mimiaga et al., 2013; Wu et al., 2013). Based on sensitivity analyses, greater CUD prevalence among those with non-specified sexual orientation is consistent with morbidity findings in broader SUD literature (Lee et al., 2015; Mereish, Lee, Gamarel, Zaller, & Operario, 2015).

Study caveats bear mentioning. These include: 1) setting representativeness, given that these are all university-based sites, 2) selection bias, as data collection that excluded those appearing intoxicated, and 3) omission of demographic indicators (i.e. education, employment, income) that interact with substance abuse to influence HIV course and outcome (Oldenburg, Perez-Brumer, & Reisner, 2014). Influence of such caveats may be mitigated by the size and diversity of this CNICS cohort, secure procedures whereby patient-reports of cannabis-related behavior were gathered, and use of an established patient-report instrument with diagnostic threshold to identify cases of CUD for which there is strong, cross-cultural empirical validation.

Conclusions

This study documents nearly half of cannabis-using HIV care enrollees as having CUD, identifies subgroups wherein CUD concentration is greater, and specifies CUD predictors among patient demographic indices. Study findings are timely, as balancing of the aforementioned pendulum that cannabis presents as both therapeutic agent and drug of abuse for PLWHA is continually challenged by progressive shifts in legislative policy (Pacula, Hunt, & Boustead, 2014). Such policies increase the need for CUD surveillance and intervention efforts in domestic HIV care settings. Given existing resource challenges faced by many HIV care settings, these findings may inform patient subgroups on whom surveillance and intervention efforts may focus.

Acknowledgments

This work was sponsored by the University of Washington Alcohol & Drug Abuse Institute with support from the Washington State I-502 Dedicated Marijuana Fund, and by the National Institute on Drug Abuse under R03 DA039719. CNICS is funded by National Institute of Allergy and Infectious Diseases under R24 AI067039, at University of Alabama at Birmingham (P30 AI027767), University of Washington (P30 AI027757), University of California San Diego (P30 AI036214), University of California San Francisco (P30 AI027763), Case Western Reserve University (P30 AI036219), John Hopkins University (P30 AI094189, U01 DA036935), Fenway Health/Harvard (P30 AI060354), and University of North Carolina Chapel Hill (P30 AI50410). The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health. The authors thank Julia C. Dombrowski for her review and comments on an initial draft of the manuscript, as well as the providers and patients from the CNICS sites for their participation in the data collection.

References

- Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Peterson KL. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology*. 2007; 68:515–521. [PubMed: 17296917]

- Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. *Journal of Behavioral Medicine*. 2014; 37:1–10. [PubMed: 23054178]
- Budney AJ, Hughes JR. The cannabis withdrawal syndrome. *Current Opinions In Psychiatry*. 2006; 19(3):233–238.
- CNICS. CFAR Network of Integrated Clinical Systems. 2016. Retrieved May 16, 2016, from www.uab.edu/cnics
- Cohen NL, Heinz AJ, Ilgen M, Bonn-Miller MO. Pain, cannabis species, and cannabis use disorders. *Journal of Studies on Alcohol and Drugs*. 2016; 77:515–520. [PubMed: 27172585]
- de Jong BC, Prentiss D, McFarland W, Machehano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. *JAIDS*. 2005; 38(1):43–46. [PubMed: 15608523]
- Fogarty A, Rowstone P, Prestage G, Crawford J, Grierson J, Kippax S. Marijuana as therapy for people living with HIV/AIDS: Social and health aspects. *AIDS Care*. 2007; 19:295–307. [PubMed: 17364413]
- Furler MD, Einderson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. *AIDS Patient Care and STDs*. 2004; 18(4):215–228. [PubMed: 15142352]
- Gruzca RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ. Recent trends in the prevalence of marijuana use and associated disorders in the United States. *JAMA Psychiatry*. 2016; 73(3):300–301. [PubMed: 26864618]
- Hartzler B, Dombrowski JC, Crane HM, Eron JJ Jr, Geng EH, Mathews WC, Donovan DM. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. *AIDS and Behavior*. (in press).
- Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering RP, Smith SM, Grant BF. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *American Journal of Psychiatry*. 2016; 173(6):588–599. [PubMed: 26940807]
- Hosek SG, Harper GW, Domanico R. Predictors of medication adherence among HIV-infected youth. *Psychology, Health, & Medicine*. 2005; 10:166–179.
- Hubbard AE, Ahern J, Fleischer NL, Van der Laan M, Lippman SA, Jewell N, Santariano WA. To GEE or not to GEE: Comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. *Epidemiology*. 2010; 21:467–474. [PubMed: 20220526]
- Hughes MD. Initial treatment of HIV infection: Randomized trials with clinical endpoints are still needed. *Journal of Infectious Diseases*. 2006; 194:542–544. [PubMed: 16897649]
- Humeniuk R, Ali R, Babor TF, Farrell M, Formigoni ML, Jittiwuikarn J, Simon S. Validation of the alcohol, smoking, and substance involvement screening test (ASSIST). *Addiction*. 2008; 103(6):1039–1047. [PubMed: 18373724]
- Lee JH, Gamarel KE, Kahler CW, Marshall BDL, Van Den Berg JJ, Bryant KJ, Operario D. Co-occurring psychiatric and drug use disorders among sexual minority men with lifetime alcohol use disorders. *Drug and Alcohol Dependence*. 2015; 151:167–172. [PubMed: 25913886]
- Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *Cochrane Database Systematic Review*. 2013; 4:CD005175.
- Marshall BDL, Operario D, Bryant KJ, Cook RL, Edelman EJ, Gaither JR, Fiellin DA. Drinking trajectories among HIV-infected men who have sex with men: A cohort study of United States Veterans. *Drug and Alcohol Dependence*. 2015; 148:69–76. [PubMed: 25596785]
- Mereish EH, Lee JH, Gamarel KE, Zaller ND, Operario D. Sexual orientation disparities in psychiatric and drug use disorders among a nationally representative sample of women with alcohol use disorders. *Addictive Behaviors*. 2015; 47:80–85. [PubMed: 25899096]
- Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, Mayer KH. Substance use among HIV-infected patients engaged in primary care in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. *American Journal of Public Health*. 2013; 103(8):1457–1467. [PubMed: 23763417]

- Oldenburg CE, Perez-Brumer AG, Reisner SL. Poverty matters: Contextualizing the syndemic condition of psychological factors and newly diagnosed HIV infection in the United States. *AIDS*. 2014; 28(18):2763–2769. [PubMed: 25418633]
- Pacula RL, Hunt P, Boustead A. Words can be deceiving: A review of variation among legally effective medical marijuana laws in the United States. *Journal of Drug Policy Analysis*. 2014; 7(1):1–19. [PubMed: 25657828]
- SAMHSA. Results from the 2010 National Household Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41. 2011 Rockville, MD.
- Wu LT, Blazer DG, Gersing KR, Burchett B, Swartz MS, Mannelli P. Comorbid substance use disorders with other Axis I and II mental disorders among treatment-seeking Asian American, Native Hawaiians/Pacific Islanders, and mixed race people. *Journal of Psychiatric Research*. 2013; 47:1940–1948. [PubMed: 24060266]
- Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Peterson KL. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology*. 2007; 68:515–521. [PubMed: 17296917]
- Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. *Journal of Behavioral Medicine*. 2014; 37:1–10. [PubMed: 23054178]
- Budney AJ, Hughes JR. The cannabis withdrawal syndrome. *Current Opinions In Psychiatry*. 2006; 19(3):233–238.
- CNICS. CFAR Network of Integrated Clinical Systems. 2016. Retrieved May 16, 2016, from www.uab.edu/cnics
- Cohen NL, Heinz AJ, Ilgen M, Bonn-Miller MO. Pain, cannabis species, and cannabis use disorders. *Journal of Studies on Alcohol and Drugs*. 2016; 77:515–520. [PubMed: 27172585]
- Fogarty A, Rowstone P, Prestage G, Crawford J, Grierson J, Kippax S. Marijuana as therapy for people living with HIV/AIDS: Social and health aspects. *AIDS Care*. 2007; 19:295–307. [PubMed: 17364413]
- Furler MD, Einderson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. *AIDS Patient Care and STDs*. 2004; 18(4):215–228. [PubMed: 15142352]
- Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ. Recent trends in the prevalence of marijuana use and associated disorders in the United States. *JAMA Psychiatry*. 2016; 73(3):300–301. [PubMed: 26864618]
- Hartzler B, Dombrowski JC, Crane HM, Eron JJ Jr, Geng EH, Mathews WC, Donovan DM. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. (under editorial review).
- Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering RP, Smith SM, Grant BF. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *American Journal of Psychiatry*. 2016; 173(6):588–599. [PubMed: 26940807]
- Hosek SG, Harper GW, Domanico R. Predictors of medication adherence among HIV-infected youth. *Psychology, Health, & Medicine*. 2005; 10:166–179.
- Hubbard AE, Ahern J, Fleischer NL, Van der Laan M, Lippman SA, Jewell N, Santariano WA. To GEE or not to GEE: Comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. *Epidemiology*. 2010; 21:467–474. [PubMed: 20220526]
- Hughes MD. Initial treatment of HIV infection: Randomized trials with clinical endpoints are still needed. *Journal of Infectious Diseases*. 2006; 194:542–544. [PubMed: 16897649]
- Humeniuk R, Ali R, Babor TF, Farrell M, Formigoni ML, Jittiwuikarn J, Simon S. Validation of the alcohol, smoking, and substance involvement screening test (ASSIST). *Addiction*. 2008; 103(6):1039–1047. [PubMed: 18373724]
- Lee JH, Gamarel KE, Kahler CW, Marshall BDL, Van Den Berg JJ, Bryant KJ, Operario D. Co-occurring psychiatric and drug use disorders among sexual minority men with lifetime alcohol use disorders. *Drug and Alcohol Dependence*. 2015; 151:167–172. [PubMed: 25913886]

- Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *Cochrane Database Systematic Review*. 2013; 4:CD005175.
- Marshall BDL, Operario D, Bryant KJ, Cook RL, Edelman EJ, Gaither JR, Fiellin DA. Drinking trajectories among HIV-infected men who have sex with men: A cohort study of United States Veterans. *Drug and Alcohol Dependence*. 2015; 148:69–76. [PubMed: 25596785]
- Mereish EH, Lee JH, Gamarel KE, Zaller ND, Operario D. Sexual orientation disparities in psychiatric and drug use disorders among a nationally representative sample of women with alcohol use disorders. *Addictive Behaviors*. 2015; 47:80–85. [PubMed: 25899096]
- Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, Mayer KH. Substance use among HIV-infected patients engaged in primary care in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. *American Journal of Public Health*. 2013; 103(8):1457–1467. [PubMed: 23763417]
- Oldenburg CE, Perez-Brumer AG, Reisner SL. Poverty matters: Contextualizing the syndemic condition of psychological factors and newly diagnosed HIV infection in the United States. *AIDS*. 2014; 28(18):2763–2769. [PubMed: 25418633]
- Pacula RL, Hunt P, Boustead A. Words can be deceiving: A review of variation among legally effective medical marijuana laws in the United States. *Journal of Drug Policy Analysis*. 2014; 7(1):1–19. [PubMed: 25657828]
- SAMHSA. Results from the 2010 National Household Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41. 2011 Rockville, MD.
- Wu LT, Blazer DG, Gersing KR, Burchett B, Swartz MS, Mannelli P. Comorbid substance use disorders with other Axis I and II mental disorders among treatment-seeking Asian American, Native Hawaiians/Pacific Islanders, and mixed race people. *Journal of Psychiatric Research*. 2013; 47:1940–1948. [PubMed: 24060266]

Table 1

Sample Demography and Conditional Probabilities of Cannabis Use Disorder

	<u>Demographic Subsample</u>	<u>Prior Use of Cannabis (%)</u>	<u>Conditional Probability of CUD</u>
Aggregate Sample	10,652	6587 (62%)	49%
<u>Patient Demography</u>			
Age-Group			
18–29 years	1254	810 (65%)	67%
30–39 years	2310	1465 (63%)	55%
40–49 years	3901	2448 (63%)	46%
50+ years	3187	1864 (59%)	42%
Gender			
Male	8882	5815 (66%)	50%
Female	1770	772 (44%)	42%
Race/Ethnicity			
Non-Hispanic White	5278	3844 (73%)	47%
NonHispanic Black	3632	1788 (49%)	52%
Hispanic	1270	686 (54%)	54%
Other	472	269 (57%)	49%
Transgender			
Yes	87	49 (56%)	47%
No	10,565	6538 (62%)	49%
Sexual Orientation (n=1716)			
Lesbian, Gay, or Homosexual	1280	1007 (79%)	48%
Straight or Heterosexual	278	175 (63%)	53%
Bisexual	95	75 (79%)	56%
'Something Else'	34	29 (85%)	69%
'Don't Know'	29	12 (41%)	67%

Table Notes: Sample consists of HIV+ persons enrolled in services and completing a patient-report assessment between 01/01/2007 – 12/31/2014; patient demography based on self-report; sexual orientation collected at three of the seven CNICS sites since 2012; 'prior use of cannabis' based on patient-reporting on the ASSIST; cases of CUD identified via validated diagnostic threshold for ASSIST cannabis involvement scores.

Table 2

Multivariate Prediction of Cannabis Use Disorder

	Beta value	95% CI (lower, upper)	Standard Error	Wald χ^2 (1)	Odds-Ratio	95% CI (lower, upper)
Age-Group						
18–29 years	1.27	(.70, 1.83)	.29	19.44***	3.54	(2.02, 6.22)
30–39 years	.56	(.09, 1.02)	.24	5.38*	1.74	(1.09, 2.78)
40–49 years	.17	(–.25, .59)	.21	.62	1.18	(.78, 1.80)
50+ years (referent)	0				1.00	
Gender						
Male	1.54	(1.01, 2.06)	.27	32.97***	4.64	(2.75, 7.84)
Female (referent)	0			1.00		
Race/Ethnicity						
Nonhispanic White	.63	(–.37, 1.63)	.51	1.53, ns	1.88	(.69, 5.11)
Nonhispanic Black	–.48	(–1.49, .54)	.52	.85, ns	.62	(.22, 1.72)
Hispanic	–.25	(–1.51, 1.01)	.64	.15, ns	.78	(.22, 2.76)
Other (referent)	0				1.00	

Table Notes: Based on aggregate sample of N=10,652 of HIV+ persons enrolled in services and completing a patient-report assessment between 01/01/2007 – 12/31/2014; patient demography based on self-report; cases of CUD identified via validated diagnostic threshold for ASSIST cannabis involvement scores; odds-ratios reflect likelihood of CUD relative to the indicated referent category; CNICS enrollment site and assessment biennia (i.e., 2007–08, 2009–10, 2011–12, 2013–14) included as covariates;

p<.001,

**
p<.01,

*
p<.05.